BioWorld

March 29, 2005

View Archived Issues

Ligand's Targretin Fails To Improve Survival In NSCLC

Ligand Pharmaceuticals Inc.'s cancer drug Targretin missed its primary endpoints in two pivotal trials evaluating the drug in front-line combination therapy to treat non-small-cell lung cancer. (BioWorld Today) Read More

FDA Approves ISTA's Xibrom To Treat Ocular Inflammation

Read More

Medicines Co. Holds Up Trials Of Blood Pressure Drug Clevelox

Read More

Halozyme Files NDA Seeking FDA Approval Of Enhanze SC

Read More

Other News To Note

Read More